NCT05741437View on ClinicalTrials.gov

A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 11, 2023

Primary Completion Date

August 31, 2023

Study Completion Date

September 5, 2023

Conditions
Type II Diabetes
Interventions
DRUG

CKD-378, QD, PO Drug: D745, D150, QD, PO

Durg: CKD-378, QD, PO Drug: D745, D150, QD, PO

Trial Locations (1)

03722

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY